Skip to content
Company Analysis

Harvard Bioscience, Inc. HBIO

A comprehensive view of key metrics, scores, and financial health for Harvard Bioscience, Inc.

Overview of Harvard Bioscience, Inc.

HBIO NCM
Healthcare Medical Instruments & Supplies Framework: Medical Devices & Diagnostics Micro Cap
Harvard Bioscience, Inc. (HBIO), is a Micro Cap company, in the Medical Instruments & Supplies industry, last closed at $8.60, about 15.3% undervalued vs fair value, +56.4% 1Y return, ranked 1035/1145 in sector.
Metrics Rev Growth -8.1% ROE -147.1% Gross Margin 57.7%
USD 8.60
-3.37%
(Delayed)
• Vol 90d: 37.3%
52-Week Range
Market Cap
$39.15M
Enterprise Value
$69.33M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 88%
Confidence: 91%
Updated: Oct 31
Top Beats
No strong beats yet

Quick Facts

Website https://www.harvardbioscience....
HQ Holliston, MA
Employees 330
Fiscal year Dec 31

Next Events

Earnings Nov 10 Call: Nov 10

Fair Value Snapshot

Bear Base Bull
$7
$10
$14
Current: $8.60 +15% vs base

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$86.5M
-8.1%%
Gross Profit
$49.9M
-8.9%%
Operating Income (GAAP)
-$48.6M
-682.2%%
EBITDA
-$46.5M
-4686.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
57.7%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Harvard Bioscience, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
37
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Stable Gross Margin Profile Gross margin stability is strong (score 0.72). Low volatility confirms durable consumable pricing.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.12). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Below-Peer Operating Margin Operating margin level is below peers (score 0.31). SG&A leverage needs improvement to close the gap.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
69
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 95% Coverage
Trade-Off Triangle Visualization A ternary plot showing HBIO's balance between Growth (15.1%), Profitability (49.5%), and Safety (35.4%). Growth 15% Safety 35% Profitability 49%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

13th percentile vs peers
13
Key Signals
Rev Growth YoY -8.1% 21p Revenue CAGR 3Y -8.6% 15p TSR -60.7% 8p EPS Growth YoY -3.48 4p Asset Growth YoY -36.8% 5p
Strengths
  • Cash Flow to Debt Ratio in top 20% of peers (3.77, 92th percentile)
Risks
  • Growth in bottom 20% of peers (percentile: 13)
  • EPS Growth YoY in bottom 20% of peers (-3.48)

Profitability

43th percentile vs peers
44
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

31th percentile vs peers
31
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Harvard Bioscience, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$9.92
- - -
+15.3% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000